GT Biopharma Inc.

NASDAQ: GTBP · Real-Time Price · USD
1.49
0.15 (11.19%)
At close: Aug 18, 2025, 10:56 AM

GT Biopharma Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-13.16M -7.6M -20.88M -58.01M
Depreciation & Amortization
n/a n/a n/a n/a
Stock-Based Compensation
230K 2.2M 7.65M 33.93M
Other Working Capital
-109K -137K 41K 863K
Other Non-Cash Items
-800K -5.28M 10K 538K
Deferred Income Tax
n/a n/a n/a n/a
Change in Working Capital
828K 1.82M -1.99M 7.94M
Operating Cash Flow
-12.9M -8.85M -15.22M -15.61M
Capital Expenditures
n/a n/a n/a n/a
Cash Acquisitions
n/a n/a n/a n/a
Purchase of Investments
12.89M n/a 12.14M -23.04M
Sales Maturities Of Investments
n/a n/a 12.14M n/a
Other Investing Acitivies
n/a -2.01M -12.14M n/a
Investing Cash Flow
12.89M -2.01M 12.14M -23.04M
Debt Repayment
n/a n/a n/a 1.21M
Common Stock Repurchased
n/a n/a -224K n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
n/a n/a n/a 16.43M
Financial Cash Flow
2.98M 6.27M -224K 42.32M
Net Cash Flow
2.96M -4.59M -3.3M 3.67M
Free Cash Flow
-12.9M -8.85M -15.22M -15.61M